Concepedia

Publication | Open Access

First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer

DOIFull Paper Access

25

Citations

28

References

2017

Year

Kazuhiro Araki, Ippei Fukada, Hiroyo Yanagi, Kokoro Kobayashi, Tomoko Shibayama, Rie Horii, Shunji Takahashi, Futoshi Akiyama, Shinji Ohno, Yoshinori Ito
The Breast

Abstract

Eribulin in combination with pertuzumab and trastuzumab was well tolerated in heavily pretreated patients. Eribulin may be a viable treatment option when used in combination with pertuzumab and trastuzumab for HER2-positive ABC patients (UMIN Clinical Trial Registry identification number, UMIN000012375).

References

YearCitations

Page 1